Biolinq | pharmaphorum

Skip to main content

Wednesday 24 June 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Biolinq

News

The Biolinq continuous glucose monitor in a person's arm

Biolinq bags FDA okay for autonomous glucose sensor

Biolinq gets an FDA green light for its autonomous, needle-free continuous glucose monitor, plus a roundup of other medtech developments.

News

Slabs of dark granite

Granite Bio makes $100m debut, and other bio financings

Our round-up of recent biotech financings includes rounds for Granite Bio, Biolinq, Etiome, Grove Biopharma, and Synthetic Design Lab.

Editor's Picks

Jazz orchestrates a $4bn cancer alliance with AbCellera

US launches probe of German 'underpayment' for medicines

UK will be first market for Sanofi's subcutaneous Sarclisa

AZ's Truqap and Roche assay cleared for PTEN prostate cancer

Hacking ring seeks to extort Novo Nordisk after cyberattack

News

NICE says Libtayo can be used for advanced cervical cancer

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company